Company News
Cantor Downgrades Replimune After FDA Rejection
Cantor Fitzgerald downgraded Replimune Group (NASDAQ: REPL) to Neutral from Overweight after FDA issued a complete response letter rejecting RP1‑nivolumab biologics license.
The FDA rejected the biolo
